BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7585590)

  • 21. Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates.
    Schott ME; Schlom J; Siler K; Milenic DE; Eggensperger D; Colcher D; Cheng R; Kruper WJ; Fordyce W; Goeckeler W
    Cancer; 1994 Feb; 73(3 Suppl):993-8. PubMed ID: 8306291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crystallographic studies and primary structure of the antitumor monoclonal CC49 Fab'.
    Abergel C; Padlan EA; Kashmiri SV; Milenic D; Calvo B; Schlom J
    Proteins; 1993 Dec; 17(4):438-43. PubMed ID: 8108385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biodistribution and dosimetry of pretargeted monoclonal antibody 2D12.5 and Y-Janus-DOTA in BALB/c mice with KHJJ mouse adenocarcinoma.
    Lubic SP; Goodwin DA; Meares CF; Song C; Osen M; Hays M
    J Nucl Med; 2001 Apr; 42(4):670-8. PubMed ID: 11337558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination.
    Wilbur DS; Chyan MK; Hamlin DK; Vessella RL; Wedge TJ; Hawthorne MF
    Bioconjug Chem; 2007; 18(4):1226-40. PubMed ID: 17583925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal brush border enzyme-cleavable linkages for low renal radioactivity levels of radiolabeled antibody fragments.
    Akizawa H; Imajima M; Hanaoka H; Uehara T; Satake S; Arano Y
    Bioconjug Chem; 2013 Feb; 24(2):291-9. PubMed ID: 23330714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro system to estimate renal brush border enzyme-mediated cleavage of Peptide linkages for designing radiolabeled antibody fragments of low renal radioactivity levels.
    Fujioka Y; Satake S; Uehara T; Mukai T; Akizawa H; Ogawa K; Saji H; Endo K; Arano Y
    Bioconjug Chem; 2005; 16(6):1610-6. PubMed ID: 16287261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of linker chemistry on the pharmacokinetics of radioimmunoconjugates.
    Quadri SM; Vriesendorp HM
    Q J Nucl Med; 1998 Dec; 42(4):250-61. PubMed ID: 9973840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Gallium-67/68-Labeled Antibody Fragment for Immuno-SPECT/PET Shows Low Renal Radioactivity Without Loss of Tumor Uptake.
    Uehara T; Yokoyama M; Suzuki H; Hanaoka H; Arano Y
    Clin Cancer Res; 2018 Jul; 24(14):3309-3316. PubMed ID: 29666303
    [No Abstract]   [Full Text] [Related]  

  • 31. Renal metabolism of 3'-iodohippuryl N(epsilon)-maleoyl-L-lysine (HML)-conjugated Fab fragments.
    Fujioka Y; Arano Y; Ono M; Uehara T; Ogawa K; Namba S; Saga T; Nakamoto Y; Mukai T; Konishi J; Saji H
    Bioconjug Chem; 2001; 12(2):178-85. PubMed ID: 11312678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Biodistribution of monoclonal antibody and Fab fragment and antitumor effect of their conjugates on hepatoma xenografts].
    Li J; Zhen Y; Yang Z
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1994 Oct; 16(5):328-33. PubMed ID: 7720121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Construction and evaluation of the tumor imaging properties of 123I-labeled recombinant and enzymatically generated Fab fragments of the TAG-72 monoclonal antibody CC49.
    Tang Y; Yang S; Gariépy J; Scollard DA; Reilly RM
    Bioconjug Chem; 2007; 18(3):677-84. PubMed ID: 17361988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer.
    Lantry LE; Cappelletti E; Maddalena ME; Fox JS; Feng W; Chen J; Thomas R; Eaton SM; Bogdan NJ; Arunachalam T; Reubi JC; Raju N; Metcalfe EC; Lattuada L; Linder KE; Swenson RE; Tweedle MF; Nunn AD
    J Nucl Med; 2006 Jul; 47(7):1144-52. PubMed ID: 16818949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy.
    Goodwin DA; Meares CF; Watanabe N; McTigue M; Chaovapong W; Ransone CM; Renn O; Greiner DP; Kukis DL; Kronenberger SI
    Cancer Res; 1994 Nov; 54(22):5937-46. PubMed ID: 7954426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
    Tolmachev V; Orlova A; Pehrson R; Galli J; Baastrup B; Andersson K; Sandström M; Rosik D; Carlsson J; Lundqvist H; Wennborg A; Nilsson FY
    Cancer Res; 2007 Mar; 67(6):2773-82. PubMed ID: 17363599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lymphoid tissue targeting of anti-HIV drugs using liposomes.
    Désormeaux A; Bergeron MG
    Methods Enzymol; 2005; 391():330-51. PubMed ID: 15721390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High molecular mass radioimmunoconjugates are promising for intraperitoneal α-emitter immunotherapy due to prolonged retention in the peritoneum.
    Rauch C; Seidl C; Schlapschy M; Skerra A; Morgenstern A; Bruchertseifer F; Senekowitsch-Schmidtke R
    Nucl Med Biol; 2012 Jul; 39(5):617-27. PubMed ID: 22381781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved renal clearance and tumor targeting of 99mTc-labeled anti-Tac monoclonal antibody Fab by chemical modifications.
    Kim MK; Jeong HJ; Kao CH; Yao Z; Paik DS; Pie JE; Kobayashi H; Waldmann TA; Carrasquillo JA; Paik CH
    Nucl Med Biol; 2002 Feb; 29(2):139-46. PubMed ID: 11823118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. (67/68)Ga-labeling agent that liberates (67/68)Ga-NOTA-methionine by lysosomal proteolysis of parental low molecular weight polypeptides to reduce renal radioactivity levels.
    Uehara T; Rokugawa T; Kinoshita M; Nemoto S; Fransisco Lazaro GG; Hanaoka H; Arano Y
    Bioconjug Chem; 2014 Nov; 25(11):2038-45. PubMed ID: 25303645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.